Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Short Interest Sector Focus: Energy Sector

As of the close of business on Thursday, 8/25, we captured the Top 10 Highest Short Interest % stocks within the Energy Sector. The average short interest for stocks within the Energy sector stands at 2.61%. Therefore, the below stocks are showing a more pessimistic outlook than their peers within the respective sector.  

As of the close of business on Thursday, 8/25, we captured the Top 10 Highest Short Interest % stocks within the Energy Sector.

The average short interest for stocks within the Energy sector stands at 2.61%. Therefore, the below stocks are showing a more pessimistic outlook than their peers within the respective sector.

 

  • VERTEX ENERGY INC    (NASDAQ:VTNR)    30.29%
  • ENERGY FUELS INC    (NYSE:UUUU)    22.08%
  • HOUSTON AMER ENERG    (NYSE:HUSA)    19.07%
  • URANIUM ENERGY COR    (NYSE:UEC)    18.29%
  • VAALCO ENERGY INC    (NYSE:EGY)    18.22%
  • KLX ENERGY SERVICE    (NASDAQ:KLXE)    13.31%
  • LAREDO PETE INC        (NYSE:LPI)    13.10%
  • CHESAPEAKE ENERGY    (NASDAQ:CHK)    12.89%
  • CNX RESOURCES CORP    (NYSE:CNX)    12.34%
  • UR ENERGY INC        (NYSE:URG)    11.60%

 

Short Interest is the percentage of a stocks’ outstanding shares being sold short, which is utilized as a gauge for stock price sentiment. When short interest increases, this is generally considered a negative “bear” market indicator, whereas when short interest decreases, this is generally considered a positive “bull” market indicator. 

Disclaimer:
The Short Interest Indicator is produced by Tidal Markets, in partnership with Benzinga Insights. The data represented is exclusive to short interest data amalgamated daily by Tidal Markets LLC and its underlying proprietary sources. The information contained herein should not be compared to, contrasted, or evaluated against other short interest data providers. ANY INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE OR IMPLY INVESTMENT ADVICE

Total
0
Shares
Related Posts
Read More

Pliant Therapeutics Earlier Announced Data From The Integris-IPF Phase 2a Trial Demonstrating Bexotegrast 320 Mg Was Well Tolerated And Achieved Statistically Significant FVC Increase In Patients With Idiopathic Pulmonary Fibrosis; Trial Met Primary An…

Pliant Therapeutics, Inc. (NASDAQ: PLRX) today announced 12-week interim data from the 320 mg dose group of INTEGRIS-IPF, a multinational, randomized, double-blind, placebo-controlled Phase 2a clinical trial of bexotegrast (PLN-74809) in patients with idiopathic pulmonary fibrosis (IPF).

PLRX